12:00 AM
Mar 20, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Status

IMC-C225: Expanded Phase II study

ImClone Systems Inc. (IMCL), New York, N.Y.
Product: IMC-C225
Business: Cancer
Therapeutic category: Antibody
Target: EGFr...

Read the full 67 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >